 |
|
|
| |
Phase IIIb, open-label, single-arm trial of darunavir/cobicistat: Week 48 subgroup analysis of HIV-1-infected, treatment-naïve adults - PK/virology/safety/tolerability
|
| |
| |
Reported by Jules Levin
Presented at the 12th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2-6 November, 2014
Karen Tashima,1 Gordon Crofoot,2 Frank L Tomaka,3 Thomas N Kakuda,3 Anne Brochot,4 Simon Vanveggel,5 Magda Opsomer,5 William Garner,6
Nicolas Margot,6 Joseph M Custodio,6 Marshall W Fordyce,6 Javier Szwarcberg6
1The Miriam Hospital, Providence, RI, USA; 2Gordon Crofoot Research, Houston, TX, USA; 3Janssen Research & Development LLC, Titusville, NJ, USA; 4Janssen Research & Development, Beerse, Belgium;
5Janssen Infectious Diseases BVBA, Beerse, Belgium; 6Gilead Sciences, Foster City, CA, USA
|
| |
|
|
|
|
|
